07 September 2018
A new report by visiongain predicts that the Global Generics Drugs market will reach $356.8bn in 2020. This forecast and others appear in Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets, published in April 2016. Visiongain is a business information provider based in London, UK.
This report examines the current and future trends in the growing generic drugs market. Population growth and changing demographics with increasing proportions of elderly people in most markets will enhance growth of the market. The rapid emergence of the middle-class in many emerging markets will also contribute to growth. Cost-pressures that encourage healthcare providers and governments to introduce policies to further encourage the use of generic drugs will further bring growth to the generics market over the years.
In this report, we examine in detail the global generic drugs market, and provide analyses and forecasts for regional and national markets. Historical revenues, where available, have also been added to strengthen our analysis and demonstrate how this market has changed. Qualitative analysis of the market is given, taking into account governmental policy and regulation, safety, features and more.
Visiongain’s report provides revenue forecasts to 2026 for the Generic Drugs market, including forecasts for leading regional and national markets: US, EU5 (Germany, UK, France, Italy and Spain), Asia-Pacific (China, Japan and India) as well as emerging markets (Brazil, Russia, Mexico, South Korea and Turkey). The report also discusses selected leading companies in the market. These companies include Teva, Mylan, Novartis (Sandoz), Sun Pharma, Pfizer, Abbott, Allergan, Fresenius Kabi, Sanofi and Aspen.
Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on email@example.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
21 September 2023
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
14 September 2023
The global Stem Cell Therapy Contract Manufacturing market was valued at US$2,495.1 million in 2022 and is projected to grow at a CAGR of 12.4% during the forecast period 2023-2033.